Tied with Cabenuva for second place was Amgen’s Lumakras, which was approved in 2021 for non-small cell lung cancer and boasted impressive therapeutic and R&D scores, but fell behind both ...

Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...

What is the Moab 240? Founded in 2017, the Moab 240 was created in memory of ultrarunner Stephen Jones, who tragically died in 2016 in an avalanche while skiing. A much-loved figure in Utah trail ...

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...

EV mobility platform ZEVO India is infusing Rs 240 crore into its business to strengthen its presence in the Indian logistics market, its top executive told ETAuto. "We are raising about Rs 240 ...

Now two KRAS inhibitors, Amgen’s sotorasib (Lumakras) and BMS/Mirati’s adagrasib (Krazati), are approved — and many more are in the clinic. But while clinicians had high hopes that these ...

During Colorectal Cancer Awareness Month, Dr. Shyam Thakkar discussed rates of this disease in young adults, the role of AI and disparities in care. After being diagnosed with colon cancer, I learned ...

Life expectancy for people with metastatic or metastasized lung cancer is low. The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung cancer (NSCLC). 25-30% of ...

Acquired resistance (AR) to Lumakras® (sotorasib), the first FDA-approved KRASi, poses a significant challenge in the treatment of KRAS G12C mutant NSCLC. Despite initial responses, patients ...